AU2021347349B2 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
AU2021347349B2
AU2021347349B2 AU2021347349A AU2021347349A AU2021347349B2 AU 2021347349 B2 AU2021347349 B2 AU 2021347349B2 AU 2021347349 A AU2021347349 A AU 2021347349A AU 2021347349 A AU2021347349 A AU 2021347349A AU 2021347349 B2 AU2021347349 B2 AU 2021347349B2
Authority
AU
Australia
Prior art keywords
mitapivat
amount
pharmaceutically acceptable
acceptable salt
pediatric subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021347349A
Other languages
English (en)
Other versions
AU2021347349A1 (en
Inventor
Cheuk-Yui LEUNG
Eric Simone
Ophelia Qiping YIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of AU2021347349A1 publication Critical patent/AU2021347349A1/en
Application granted granted Critical
Publication of AU2021347349B2 publication Critical patent/AU2021347349B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021347349A 2020-09-25 2021-09-24 Pharmaceutical formulation Active AU2021347349B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063083834P 2020-09-25 2020-09-25
US63/083,834 2020-09-25
US202063107196P 2020-10-29 2020-10-29
US63/107,196 2020-10-29
US202163238483P 2021-08-30 2021-08-30
US63/238,483 2021-08-30
PCT/US2021/051957 WO2022067039A1 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
AU2021347349A1 AU2021347349A1 (en) 2023-06-08
AU2021347349B2 true AU2021347349B2 (en) 2026-08-13

Family

ID=78179552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021347349A Active AU2021347349B2 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Country Status (10)

Country Link
US (1) US20230338283A1 (cg-RX-API-DMAC7.html)
EP (1) EP4216956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542701A (cg-RX-API-DMAC7.html)
KR (1) KR20230074536A (cg-RX-API-DMAC7.html)
AU (1) AU2021347349B2 (cg-RX-API-DMAC7.html)
CA (1) CA3196829A1 (cg-RX-API-DMAC7.html)
IL (1) IL301596A (cg-RX-API-DMAC7.html)
MX (1) MX2023003431A (cg-RX-API-DMAC7.html)
TW (1) TW202228691A (cg-RX-API-DMAC7.html)
WO (1) WO2022067039A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019104134A1 (en) * 2017-11-22 2019-05-31 Agios Pharmaceuticals, Inc. Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019104134A1 (en) * 2017-11-22 2019-05-31 Agios Pharmaceuticals, Inc. Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Also Published As

Publication number Publication date
AU2021347349A1 (en) 2023-06-08
MX2023003431A (es) 2023-05-12
EP4216956A1 (en) 2023-08-02
TW202228691A (zh) 2022-08-01
CA3196829A1 (en) 2022-03-31
KR20230074536A (ko) 2023-05-30
WO2022067039A1 (en) 2022-03-31
US20230338283A1 (en) 2023-10-26
IL301596A (en) 2023-05-01
JP2023542701A (ja) 2023-10-11